Latest Regulatory News

betr Entertainment reported a $13.2 million EBITDA loss in H1 FY26 due to strategic investments and favourable customer outcomes but projects a strong rebound with a $13-19 million EBITDA target for FY27.

Urbanise.com Limited reported a 22% revenue increase in Q2 FY2026, driven by its strategic partnership with National Australia Bank and ongoing development of its Data and Payments Integration Services platform. Despite short-term cash outflows, the company targets positive operating cash flow by FY2027.

Sunrise Energy Metals advances its Syerston Scandium Project with a robust updated Ore Reserve supporting a 32-year mine life, alongside significant financing commitments and a strategic offtake option with Lockheed Martin.

Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.

Horizon Oil reported an 18% rise in production and sales volumes in Q2 FY26, driven by its first full quarter of Thailand asset output. The company also maintained strong cashflow, paid a final FY25 dividend, and secured a long-term gas supply agreement in Australia’s Northern Territory.

MEC Resources has bolstered its stake in Advent Energy with a $1.55 million loan while navigating a pivotal Federal Court hearing on the PEP 11 Joint Venture. Meanwhile, progress on Clean Hydrogen Technology signals potential growth avenues.

Bass Oil Limited reported a 7.9% rise in quarterly oil sales revenue and a 7.4% increase in production, alongside a pivotal gas sales agreement with Origin Energy for the Vanessa gas field, pending regulatory approval.

D3 Energy has reported encouraging progress in its South African helium and methane operations, highlighted by improved gas flow rates from the Nooitgedacht Major well and an upgraded US OTCQX listing to broaden investor reach.

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

Equatorial Resources has completed the final hearing in its high-stakes arbitration against the Republic of Congo and is pursuing clarity on permit cancellations in Guinea, all while maintaining a solid cash reserve.

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.